维利西呱对慢性心力衰竭患者的影响  

Effect of Vericiguat on Patients with Chronic Heart Failure

作　　者：孙丽娜 宗书峰 张艳华 SUN Lina;ZONG Shufeng;ZHANG Yanhua(Department of Cardiology,Zhengzhou Central Hospital Affiliated to Zhengzhou University,Zhengzhou 450000,China)

机构地区：[1]郑州大学附属郑州中心医院心血管内科,河南郑州450000

出　　处：《河南医学研究》2025年第5期911-915,共5页Henan Medical Research

摘　　要：目的分析维利西呱对慢性心力衰竭(CHF)患者心功能及血清嗜铬粒蛋白A(CgA)、补体C1q肿瘤坏死因子相关蛋白9(CTRP9)、Nexilin水平的影响。方法回顾性分析2023年1—12月郑州大学附属郑州中心医院收治的78例CHF患者资料,按治疗方案将采用常规抗心力衰竭方案治疗的39例患者列为对照组,将采用常规抗心力衰竭方案联合维利西呱治疗的39例患者列为研究组。比较两组临床疗效、心功能[心脏指数(CI)、左室射血分数(LVEF)、氨基末端脑利钠肽前体(NT-proBNP)、心肌能量消耗(MEE)]、血管内皮功能[内皮素-1(ET-1)、降钙素基因相关肽(CGRP)、一氧化氮(NO)]、血清CgA、CTRP9、Nexilin及不良反应。结果研究组临床总有效率[94.87%(37/39)]高于对照组[79.49%(31/39)](P<0.05);研究组治疗后NT-proBNP、MEE低于对照组,CI、LVEF高于对照组(P<0.05);研究组治疗后ET-1低于对照组,CGRP、NO高于对照组(P<0.05);研究组治疗后CgA、Nexilin低于对照组,CTRP9高于对照组(P<0.05);研究组不良反应发生率[15.38%(6/39)]与对照组[10.26%(4/39)]比较,差异无统计学意义(P>0.05)。结论维利西呱治疗CHF患者安全有效,可调节血清CgA、CTRP9、Nexilin表达,改善血管内皮功能,改善心功能。Objective To analyze the effects of vericiguat on cardiac function and serum levels of chromogranin A(CgA),complement C1q tumor necrosis factor related protein 9(CTRP9)and Nexilin in patients with chronic heart failure(CHF).Methods The data of 78 patients with CHF in Zhengzhou Central Hospital Affiliated to Zhengzhou University from January to December 2023 were retrospectively analyzed.Among them,39 patients who treated with conventional anti heart failure scheme were listed as the control group,and 39 patients who treated with conventional anti heart failure scheme combined with Vilixiapine were listed as the study group according to the treatment scheme.The clinical efficacy,cardiac function[cardiac index(CI),left ventricular ejection fraction(LVEF),N-terminal pro brain natriuretic peptide(NT-proBNP),myocardial energy expenditure(MEE)],vascular endothelial function[endothelin-1(ET-1),calcitonin gene-related peptide(CGRP),nitric oxide(NO)],serum CgA,CTRP9,Nexilin and adverse reactions were compared between the two groups.Results The total effective rate of the study group was 94.87%(37/39),which was higher than that of the control group[79.49%(31/39)](P<0.05).After treatment,NT-proBNP and MEE in the study group were lower than those in the control group,while CI and LVEF in the study group were higher than those in the control group(P<0.05).After treatment,ET-1 in the study group was lower than that in the control group,while CGRP and NO in the study group were higher than those in the control group(P<0.05).After treatment,the levels of CgA and Nexilin in the study group were lower than those in the control group,and CTRP9 was higher than that in the control group(P<0.05).The incidence of adverse reactions in the study group was 15.38%(6/39),which was not significantly different from that in the control group[10.26%(4/39)](P>0.05).Conclusion Vilixiapine is safe and effective in the treatment of CHF patients,which can regulate the expression of serum CGA,CTRP9 and Nexilin,improve vascular endothelial function an

关 键 词：慢性心力衰竭 维利西呱 心功能 血清嗜铬粒蛋白A 补体C1q肿瘤坏死因子相关蛋白9 Nexilin 

分 类 号：R541.6[医药卫生—心血管疾病]